Deep Multiple Instance Learning Model to Predict Outcome of Pancreatic Cancer Following Surgery.

Fiche publication

Date publication

décembre 2024

Journal

Biomedicines

Auteurs

Membres identifiés du Cancéropôle Est :
Pr BORG Christophe , Pr GHIRINGHELLI François , Mr MONNIEN Franck , Mme TRUNTZER Caroline , Dr VIENOT Angélique , Dr DERANGERE Valentin , Pr BIBEAU Frédéric , Dr MOLIMARD Chloé

Tous les auteurs :
Truntzer C, Ouahbi D, Huppé T, Rageot D, Ilie A, Molimard C, Beltjens F, Bergeron A, Vienot A, Borg C, Monnien F, Bibeau F, Derangère V, Ghiringhelli F

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/39767661

Résumé

: Pancreatic ductal adenocarcinoma (PDAC) is a cancer with very poor prognosis despite early surgical management. To date, only clinical variables are used to predict outcome for decision-making about adjuvant therapy. We sought to generate a deep learning approach based on hematoxylin and eosin (H&E) or hematoxylin, eosin and saffron (HES) whole slides to predict patients' outcome, compare these new entities with known molecular subtypes and question their biological significance; : We used as a training set a retrospective private cohort of 206 patients treated by surgery for PDAC cancer and a validation cohort of 166 non-metastatic patients from The Cancer Genome Atlas (TCGA) PDAC project. We estimated a multi-instance learning survival model to predict relapse in the training set and evaluated its performance in the validation set. RNAseq and exome data from the TCGA PDAC database were used to describe the transcriptomic and genomic features associated with deep learning classification; : Based on the estimation of an attention-based multi-instance learning survival model, we identified two groups of patients with a distinct prognosis. There was a significant difference in progression-free survival (PFS) between these two groups in the training set (hazard ratio HR = 0.72 [0.54;0.96]; = 0.03) and in the validation set (HR = 0.63 [0.42;0.94]; = 0.01). Transcriptomic and genomic features revealed that the poor prognosis group was associated with a squamous phenotype. : Our study demonstrates that deep learning could be used to predict PDAC prognosis and offer assistance in better choosing adjuvant treatment.